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RESEARCH ARTICLE Open Access
HIV vaccine acceptability among high-risk drug
users in Appalachia: a cross-sectional study
April M Young1,2,3*, Ralph J DiClemente3, Daniel S Halgin4, Claire E Sterk3 and Jennifer R Havens2
Abstract
Background: A vaccine could substantially impact the HIV epidemic, but inadequate uptake is a serious concern.
Unfortunately, people who use drugs, particularly those residing in rural communities, have been underrepresented
in previous research on HIV vaccine acceptability. This study examined HIV vaccine acceptability among high-risk
drug users in a rural community in the United States.
Methods: Interviewer-administered questionnaires included questions about risk behavior and attitudes toward HIV
vaccination from 433 HIV-negative drug users (76% with history of injection) enrolled in a cohort study in Central
Appalachia. HIV vaccine acceptability was measured on a 4-point Likert scale. Generalized linear mixed models
were used to determine correlates to self-report of being “very likely” to receive a 90% effective HIV vaccine
(i.e. “maximum vaccine acceptability”, or MVA). Adjusted odds ratios (AORs) and corresponding 95% confidence
intervals (CIs) are reported.
Results: Most (91%) reported that they would accept a preventive HIV vaccine, but concerns about cost, dosing,
transportation constraints, vaccine-induced seropositivity, and confidentiality were expressed. Cash incentives,
oral-administration, and peer/partner encouragement were anticipated facilitators of uptake. In multivariate analysis,
men were significantly less likely to report MVA (AOR: 0.33, CI: 0.21 – 0.52). MVA was more common among participants
who believed that they were susceptible to HIV (AOR: 2.31, CI: 1.28 – 4.07), that an HIV vaccine would benefit them (AOR:
2.80, CI: 1.70 – 4.64), and who had positive experiential attitudes toward HIV vaccination (AOR: 1.85, CI: 1.08 – 3.17). MVA
was also more common among participants who believed that others would encourage them to get vaccinated and
anticipated that their behavior would be influenced by others' encouragement (AOR: 1.81, 95% 1.09 – 3.01).
Conclusions: To our knowledge, this study was among the first to explore and provide evidence for feasibility of
HIV vaccination in a rural, high-risk population in the United States. This study provides preliminary evidence that
gender-specific targeting in vaccine promotion may be necessary to promoting vaccine uptake in this setting,
particularly among men. The data also underscore the importance of addressing perceived risks and benefits, social
norms, and logistical constraints in efforts to achieve widespread vaccine coverage in this high-risk population.
Keywords: HIV, Vaccination, AIDS vaccines, HIV vaccines, Attitude, Drug users, Psychological theory, Rural health
Background
Since 1987, the scientific community has been in pursuit
of an effective HIV vaccine [1]. In response to the possi-
bility that an HIV vaccine is on the horizon, researchers
have mobilized to examine the feasibility of disseminat-
ing the vaccine. In high-risk populations around the
world, numerous studies on HIV vaccine acceptability
have been conducted, but people who use drugs have been
underrepresented. Recent research investigating attitudes
toward compulsory HIV vaccination among high-risk indi-
viduals in Los Angeles found that that people who inject
drugs (PWID) were significantly less likely to endorse uni-
versal vaccination or vaccination of all children or adults
compared to their non-injecting counterparts [2]. The au-
thors point out that the strong opposition to compulsory
vaccination policies among PWID may be indicate future
challenges in HIV vaccine acceptance and dissemination
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[2], thus reinforcing the need for additional research. Of
the 15 quantitative studies from the US included in a re-
cent review [3], only three included drug users [4-6]; none
of which reported results stratified by drug use. Qualitative
studies on HIV vaccine acceptability are equally limited, as
nearly all of those involving people who use drugs have
been conducted in one setting (i.e. Los Angeles) [6-11].
There are no studies to date evaluating HIV vaccine ac-
ceptability in a high-risk, rural drug-using population in
the US. National surveillance data indicate that while the
prevalence of AIDS has gradually declined in most urban
areas since the mid 1980's, the number of cases continues
to slowly increase in many rural communities, particularly
in the South [12,13]. Given the historically low prevalence
of HIV in rural areas and the common misconception that
HIV is an “urban problem”, many rural communities are
unequipped to deal with the social, economic, and health-
care burden posed by an increase in HIV.
Central Appalachia, which encompasses some of the
most economically distressed counties in the US [14],
would face many of the challenges posed by an increase in
HIV and AIDS. The Appalachian region is characterized
by marked health disparities [15], an under-resourced
health infrastructure [15], and prevalent misuse of pre-
scription drugs [16-18]. While HIV prevalence is currently
low in this population [19], recent evidence from Eastern
Kentucky, in Central Appalachia, suggested that many
nonmedical prescription drug users were infected with
hepatitis C [20], had engaged in injection drug use (IDU)
[21] and frequent unprotected sex [22], and were embed-
ded in a highly cohesive and centralized risk network that
could facilitate HIV transmission [23]. Given these risk
factors, stigma surrounding HIV [24], and myriad cultural
and socioeconomic complexities, Central Appalachia is a
setting in which greater knowledge of potential barriers
and facilitators to HIV vaccine acceptability will be essen-
tial in achieving adequate coverage. The purpose of this
study was to examine demographic, behavioral, and psy-
chosocial correlates to HIV vaccine acceptability among a
sample of HIV negative, high-risk drug users in Central
Appalachia.
Methods
Sample
The data used for this analysis were collected during the
24-month assessment of the longitudinal Social Networks
among Appalachian People (SNAP) study. Recruitment
and assessment are described in detail elsewhere [20,23,25].
To be eligible, participants were required to be age 18 or
older, reside in Appalachian Kentucky, and to have used
prescription opioids, heroin, crack/cocaine, or metham-
phetamine to get high in the prior 30 days. Participants
(n = 503) were recruited from rural Appalachian Kentucky
using respondent-driven sampling and data were collected
using questionnaires administered by trained community-
based staff. Participants completed follow-up interviews
and HIV testing at 6-month intervals. The 24-month inter-
view was completed by 435 participants between March
2012 and May 2013.
Measures
Following their 24-month interview, participants (n = 433)
were invited to complete an interviewer-administered
questionnaire on their attitudes toward HIV vaccination
(two who were interviewed in jail were not invited due to
time-constraints). All invited participants consented and
were compensated $35 for participation. Before the ques-
tionnaire, interviewers read a script reminding them that
HIV can be transmitted through sharing drug equipment
and having unprotected sex, that HIV is the cause of
AIDS, and that there is currently no cure. The script in-
formed participants that the vaccine referred to through-
out the questionnaire would not cure HIV, but would
prevent acquisition. A 90% efficacy level was specified for
the questions presented in these analyses. The University
of Kentucky's Institutional Review Board approved the
protocol.
HIV vaccine acceptability
HIV vaccine acceptability was assessed with: “Imagine that
an affordable HIV vaccine was approved and made avail-
able to you in the next 12 months. This vaccine would
prevent you from getting HIV almost all of the time (90%
effective). How likely would you be to get this vaccine?”
followed by a 4-point Likert scale ranging from ‘very un-
likely’ to ‘very likely’. Due to skewness, the responses were
dichotomized for analysis (0 = Very unlikely/Unlikely/
Likely; 1 = Very likely). Given the debatable association be-
tween these intentions and actual behavior [26], this con-
servative dichotomization may provide a better indication
of future uptake. Hereafter, those who were 'very likely' to
accept the vaccine are referred to as reporting “maximum
vaccine acceptability” (MVA).
Vaccine characteristics
Participants were also asked about vaccine characteris-
tics identified in previous research as factors relevant to
acceptability [3,5,6,27,28]. Items assessed willingness to
pay (continuous), minimum acceptable vaccine efficacy
(ordinal in increments of 10%), and whether cash incen-
tives, dosing (multiple vs. single), administration (oral vs.
injected), and/or vaccine-induced positive results on fu-
ture HIV tests would affect vaccine acceptability.
Demographic, behavioral, and psychosocial measures
Basic demographic and behavioral data were also col-
lected (listed in Table 1). The psychosocial measures
were based on a modified version [29] of the Integrative
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Model (IM) [30], which posits that behavior is directly
affected by intention. Intention is influenced by atti-
tudes, perceived norms, and personal agency, which are
in turn influenced by background factors (e.g., demo-
graphic, behavioral, and other contextual characteristics).
Table 2 describes the items and coding scheme used to as-
sess the following: attitudes (instrumental and experien-
tial), subjective norms (descriptive and injunctive), and
personal agency (perceived behavioral control and self-
efficacy). Due to skew in the response distribution of the
four-point Likert-scale and semantic differential scale
measures, items were dichotomized at the mid-point of
the ‘forced choice’ style response options such that a value
of 1 indicated a positive response and a value of 0 indi-
cated a negative response. Experiential and instrumental
attitudes refers to emotional and cognitive responses, re-
spectively, to performing a behavior [31]. Experiential atti-
tudes were examined with semantic differential scale
items used in a similar study [32]. The instrumental atti-
tude measures were adapted from the Health Belief Model
[33]; these include perceived severity of and susceptibility
to HIV, and perceived benefits of and barriers to HIV
vaccination.
Injunctive norms are a person's beliefs about and motiv-
ation to comply with what others think he/she should do.
Descriptive norms refer to a person's perceptions about
others' behavior and his/her motivation to comply with (i.e.
imitate) their actions [34,35]. Descriptive and injunctive
norms are each comprised of two sub-constructs: norma-
tive beliefs and motivation to comply. Self-efficacy and per-
ceived behavioral control were also examined. Self-efficacy
is the belief in one's general capabilities to exercise control
over his/her behavior [36], while perceived behavioral con-
trol focuses on one's abilities to perform a behavior in light
of various barriers [37].
Statistical analyses
Given potential autocorrelation among responses, general-
ized linear mixed models were used. Models were esti-
mated using the PROC GLIMMIX [38] procedure (SAS
software, version 9.3) with a random effect for subject and
Laplace approximation [39]. To adjust for potential biases
presented by respondent-driven sampling [40,41], individu-
alized weights computed in RDSAT 7.1 (Ithaca, NY) [42]
were used in all analyses. The weights were based on indi-
vidual network size and partition analysis on the dependent
variable using enhanced data smoothing and 25,000 boot-
strap iterations. Odds ratios (ORs), adjusted odds ratios
(AORs), and 95% confidence intervals (CIs) were reported.
Each demographic and behavioral variable was assessed in-
dependently for its association with the outcome, and those
reaching significance (p < 0.05) were entered into multivari-
ate analyses. Due to the a priori nature of the IM, all psy-
chosocial variables were entered into multivariate analyses
regardless of bivariate significance, as suggested in previous
research [43].
Results
Descriptive demographic and behavioral data are pre-
sented in Table 1. Briefly, the median age was 34 years
(range: 21–68), 55% were male, and most respondents
were White (94%); the latter is reflective of the demo-
graphic profile of Central Appalachia [44]. Most (76%)
reported a lifetime history of IDU and 34% reported re-
cent IDU (past 6 months). Receptive and distributive
needle sharing were uncommon, but 13% had shared
Table 1 Demographic and behavioral characteristics of
the sample (n = 433)
Characteristic N (%)
Demographic
Male 239 (55.2)
Age – median (IQR) 34 (29 – 41)
White 407 (94.0)
High school graduate 251 (58.0)
Married 111 (25.6)
Unemployed 169 (39.0)
Income in past 30 daysa – median (IQR) $698 (200 – 1100)
Uninsured 285 (65.8)
Drug use in past 6 months
Nonmedical use of prescription drugsb 368 (95.0)
Cocaine 51 (11.8)
Methamphetamine 35 (8.1)
Heroin 23 (5.3)
Crack 14 (3.2)
IDU-related behaviors (past 6 months)
Injected drugs at least once 146 (33.7)
Injected with unclean needle 33 (7.6)
Gave/loaned/sold an unclean needle 16 (3.7)
Shared injection equipmentc 55 (12.7)
Sexual behavior (past 6 months)
Number of sex partners
Zero 76 (17.6)
One partner 254 (58.7)
Two partners 56 (12.9)
Three or more partners 47 (10.9)
Unprotected sex with at least one partner 308 (71.1)
Unprotected sex with PWID 85 (19.6)
IQR: interquartile range; PWID: person who injects drugs; IDU: injection drug use.
aIncludes income from employment, unemployment compensation, welfare,
pension/social security, child support, friends/family, and illegal activities.
bIncludes nonmedical use of methadone, OxyContin, oxycodone,
buprenorphine, Roxicodone, hydrocodone, other opiates (e.g., Neurontin,
Ultram, morphine, Demerol, Opana, Embeda, Avinza), and benzodiazepines.
c Cookers, cottons, and/or rinse water.
Young et al. BMC Public Health 2014, 14:537 Page 3 of 10
http://www.biomedcentral.com/1471-2458/14/537
other injection paraphernalia. Approximately 24% re-
ported multiple sex partners in the past 6 months and
71% had unprotected sex, including 20% who had done
so with PWID.
Attitudes toward HIV and HIV vaccination
Most reported that they would be very likely (59%) or likely
(32%) to receive an HIV vaccine. Psychosocial attitudes are
shown in Table 2 and anticipated barriers, stratified by gen-
der, are displayed in Figure 1. Of note, men were signifi-
cantly more likely to report cost, requirement for multiple
doses, and time as barriers to vaccine acceptability; women
were more likely to report that there were no barriers to
vaccine acceptability. Overall, 76% were unsure or only
somewhat sure that they could get vaccinated if they had to
pay out-of-pocket, travel out of town to get it (58%), or if
their friends/partner were unsupportive (39%). Most (83%)
reported that most people they knew would accept the vac-
cine, but only 51% would be more likely to accept the vac-
cine if most people did so. Similarly, 94% believed that
most people would be supportive of their vaccination and
60% would be more likely to be vaccinated if most people
encouraged them.
Table 3 describes attitudes toward specific vaccine char-
acteristics. Most reported that requirement for multiple
doses would not influence vaccine acceptability; however,
44% reported that they would be more likely to accept an
orally-administered vaccine. Most (62%) reported that they
Table 2 Psychosocial attitudes about HIV vaccination in sample of rural drug users
Construct Measure Dichotomized response N (%)
Attitudes (n = 433)
Severity In your opinion, how serious would it be if you were infected with HIV?b Very/Extremely Serious 427 (98.6)
Susceptibility If you did not get a vaccine, how likely do you think you
would be to get HIV in your lifetime?b
Likely/Very Likely 100 (23.1)
Benefits In your opinion, how much would an HIV vaccine benefit you?c Some/A lot 313 (72.3)
Barriers What factors would make it difficult for you to
receive the HIV vaccine? [see Figure 1]
[Endorsed at least one barrier] 344 (79.4)
Experiential [3-items] For me, getting an HIV vaccine would be… ["stressful -
relaxing", “frightening – comforting”, “irresponsible – responsible”]a
[Positive rating on all three items] 343 (79.2)
Subjective norms (n = 432)
Descriptive norm Affirmative response on the
following two items
195 (45.1)
Normative belief If an HIV vaccine became available, most people important
to me would get it.d
Agree/Strongly Agree 358 (82.9)
Motivation to comply If most people got the HIV vaccine, would you be [More likely
to get it/Less likely to get it/Would not affect my decision]e
More likely to get it 218 (50.5)
Injunctive norm Affirmative response on the
following two items
251 (58.1)
Normative belief Most people important to me would be supportive
of me getting the HIV vaccine.d
Agree/Strongly Agree 408 (94.4)
Motivation to comply If most people encouraged you to get the HIV vaccine, would you be
[More likely to get it/Less likely to get it/Would not affect my decision]e
More likely to get it 256 (59.3)
Personal agency
Behavioral control How much personal control do you feel that you would
have over getting the HIV vaccine?f
A lot/Complete control 276 (63.7)
Self-efficacy How sure are you that you could get the HIV vaccine if …g Affirmative response each
of the following 3 items
83 (19.2)
…you had to pay for it out of pocket? Very/Extremely Sure 105 (24.2)
…you had to travel out of town to get it? Very/Extremely Sure 184 (42.5)
…your friends/partners did not want you to get it? Very/Extremely Sure 266 (61.4)
aMeasured on 4-point semantic differential scales; dichotomized where 1 = rating of three or four on all items, 0 = rating of one or two on at least one item.
bMeasured on 4-point scale dichotomized where: 0 = Very unlikely/Unlikely, 1 = Likely/Very likely.
cMeasured on 4-point scale dichotomized where: 0 = Not at all/Little, 1 = Some/a lot.
dMeasured on 4-point scale dichotomized where 0 = Strongly disagree/Disagree, 1 = Agree/Strongly agree.
eDichotomized where 0 = Less likely to get it/Would not affect my decision, 1 = More likely to get it.
fMeasured on 4-point scale dichotomized where 0 = No control/Some control, 1 = A lot of control/Complete control.
gEach measured on 4-point scales dichotomized where 0 = Not sure at all/Somewhat sure, 1 = Very sure/Extremely sure. Total measure was dichotomized where
1 = rating of one on all items, 0 = rating of zero on at least one item.
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would be more likely to get vaccinated if there was a cash
incentive to do so; the median incentive amount necessary
to motivate vaccination was $50. The majority (56%) re-
ported that the vaccine would need to be 90% effective be-
fore they would agree to be vaccinated and 18% reported
that the vaccine would need to provide complete protec-
tion. Nearly all (93%) were willing to pay for a 90% effective
vaccine; the median price participants were willing to pay
was $100.
Bivariate and multivariate results
Bivariate results are presented in Table 4. Men and older
participants were significantly less likely to report MVA.
Injection drug use, use of an unclean needle, and unpro-
tected sex with PWID in the past 6 months was posi-
tively associated with MVA. Perceived susceptibility to
HIV, perceived benefit of the vaccine, positive experien-
tial attitudes, and perceived behavioral control were also
positively associated with MVA. Respondents reporting
that people important to them would accept an HIV vac-
cine and that they would be more likely to accept the
vaccine if others did so were more likely to report MVA.
Similarly, those who believed that people would encour-
age them to receive the vaccine and who reported being
more likely to accept the vaccine if others encouraged
them were nearly twice as likely to report MVA.
Multivariate results are described in Table 5. Control-
ling for other variables in the model, men were less
likely to report MVA (AOR: 0.33, CI: 0.21 - 0.52). Par-
ticipants who believed they were susceptible to HIV
(AOR: 2.31, CI: 1.28 - 4.17), perceived that the vaccine
would benefit them (AOR: 2.80, CI: 1.70 - 4.64), and re-
ported positive experiential attitudes (AOR: 1.85, CI:
1.09 - 3.01) were significantly more likely to report
MVA. Injunctive norms were also positively associated
with vaccine acceptability (AOR: 1.81, CI: 1.09 – 3.01).
Discussion
In this sample of rural drug users, 91% were likely or
very likely to accept a 90% effective, preventive HIV
vaccine. This percentage is comparable to that found in
other urban and suburban populations in the US [45-47].
Men were significantly less likely to indicate that they were
very likely to receive an HIV vaccine, after adjustment for
behavioral characteristics and psychosocial constructs.
Previous research on the association between gender and
HIV vaccine acceptability is mixed, with one study finding
that acceptability was higher among women [27] and an-
other finding that it was higher among men [48]. Research
conducted among high-risk adults in Los Angeles identi-
fied gender differences in concerns and motivations sur-
rounding HIV vaccination (e.g., women were more likely
to be influenced by factors related to their intimate rela-
tionships and experiences with healthcare providers, while
men were more influenced by peer perceptions and risk of
vaccine-induced seropositivity), but no significant associ-
ation between gender and vaccine acceptability [49]. In
the present study, differences in vaccination concerns, spe-
cifically those related to perceived barriers, may play an
important role in the observed gender difference in vac-
cine acceptability. Men were significantly more likely to
report that cost, requirement for multiple doses (vs. a sin-
gle dose), and time to visit the clinic would be barriers to
vaccine acceptability. Post-hoc analysis to investigate
these patterns revealed no significant gender differences
in unemployment or total monthly income; however,
men reported significantly more monthly income from
employment and women reported significantly more in-
come from partners, peers, family, and child support. Men
were also more likely to report being uninsured. Interest-
ingly, there was no gender difference in the amount partic-
ipants were willing to pay for the vaccine. These patterns
may indicate that while men and women have similar total
gross incomes and willingness to pay, men have less net
income to use for purchasing an HIV vaccine and the in-
surance coverage to reduce out-of-pocket costs.
Findings regarding the association between gender and
barriers posed by dosing and time constraints would seem
to indicate that men anticipate experiencing other logis-
tical obstacles to accessing vaccination. Unavailability of
Figure 1 Anticipated barriers to HIV vaccine acceptability among men and women (n = 433). An asterisk (*) indicates a statistically
significant difference (p < 0.05) between men and women based on chi-square analysis.
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time to visit the clinic for one or multiple doses may be re-
lated to a number of factors, including employment. Post-
hoc analyses revealed no association between gender and
past 6-month unemployment or full-time employment,
but men were more likely to report part-time, irregular
day work. The location, hours, and nature of this work is
largely unknown, as are details about additional obliga-
tions that could compete with time available to seek vac-
cination. Although gender differences in psychosocial
constructs aside from perceived barriers (e.g., perceived
susceptibility to HIV, perceived severity of HIV) were not
observed, it is important to note that perceived and/or ac-
tual barriers to vaccination are likely only part of the con-
fluence of factors that could contribute to gender
differences in HIV vaccine acceptability in this and other
settings. In this setting, a “one-size-fits-all” [50] approach
to mitigating barriers to HIV vaccination may not be ap-
propriate. Strategies that consider possible gender differ-
ences in constraints on HIV vaccine acceptance and, in
turn, “meet men and women where they are” psychologic-
ally, socially, and geographically should be developed.
These approaches may include strategic location of vac-
cine dissemination sites (e.g., at worksites, clinics, mobile
units), varied hours of availability, and payment structures
that limit out-of-pocket costs to those with and without
insurance.
Given their low income and high rate of unemployment,
it is unsurprising that most participants reported that cost
would be a barrier to vaccine acceptability. Cost has been
identified as an important influence in HIV vaccine ac-
ceptability in many [3,27,28], but not all [5,51] previous
studies. Interestingly, participants in one study believed
that the vaccine should be given at some cost, as free ser-
vices were often perceived as inferior to those that were
purchased [52]. Nearly all participants in the present study
were willing to pay for a 90% effective HIV vaccine, but
only one-third would be able to afford out-of-pocket costs
exceeding $100. Though some research has suggested that
cost may not be as strongly associated with acceptability
as are other vaccine characteristics [5], in this setting,
minimization of out-of-pocket costs would be critical to
achieving adequate coverage.
The majority (60%) reported that a modest cash incen-
tive (less than $50) would improve their likelihood of
accepting the vaccine. Previous research among PWID
demonstrated that monetary incentives can improve com-
pliance with a three-dose hepatitis B vaccine regimen [47];
the cost-effectiveness of a similar approach to HIV vaccin-
ation should be considered. Monetary incentives may as-
sist in offsetting logistical costs, such as transportation,
which was reported as a barrier to acceptability by a siz-
able minority of participants. This finding underscores, as
has previous research [3], the importance of minimizing
logistical constraints on accessing vaccination. However,
this must be coupled with interventions which address
concerns regarding confidentiality; nearly one in eight
were concerned that providers would disclose their vac-
cination status to others. Participants in several previous
studies have reported concern about peers’ negative social
reactions to HIV vaccination [7,49,52-55], though less is
known about participants’ confidentiality concerns related
to healthcare providers administering the vaccine. Partici-
pants in a qualitative study in Los Angeles reported con-
cern about being seen at vaccine dissemination sites [7] and
one study in Thailand found that PWID were concerned
Table 3 Characteristics of HIV vaccination that could
facilitate or hinder vaccine acceptability
Characteristic N(%)
Price (USD) willingness to pay for a 90% effective HIV vaccine
$0 30 (6.9)
$1 - $50 126 (29.1)
$51 - $100 132 (30.5)
$101 - $200 57 (13.2)
$201 - $500 51 (11.8)
$501 - $1000 28 (6.5)
Greater than $1000 9 (2.1)
Efficacy required before participant would accept
an HIV vaccine (n = 423)a
Less than 50% 5 (1.2)
50% 37 (8.7)
60% 5 (1.2)
70% 13 (3.1)
80% 52 (12.3)
90% 237 (56.0)
100% 74 (17.5)
Factors that would make participant less likely to get
the vaccine (n = 431)
Requirement for multiple doses (versus single dose) 86 (20.0)
Caused future HIV test results to be positive 221 (51.3)
Factors that would make participant more likely to get
the vaccine
Cash incentive (n = 431) 269 (62.4)
Amount necessary to motivate vaccination (USD) (n = 269)
Less than $20 16 (5.9)
$20 - $50 147 (54.6)
$51 - $100 81 (30.1)
$101 - $500 18 (6.7)
$501 - $1000 4 (1.5)
$1001 - $2000 2 (0.7)
$10,000 1 (0.4)
Orally administered rather than injected (n = 430) 190 (44.2)
aMissing data include nine participants who reported that they would not
accept the vaccine regardless of efficacy.
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about being seen at vaccine dissemination locations due to
fear of legal consequences (e.g., arrest) [55]. In this and
other settings, appropriate selection of vaccine dissemin-
ation sites as well as intensive training of providers about
confidentiality will be critical to ensuring adequate vaccine
coverage among high-risk populations.
Findings regarding the importance of perceived social
norms may also inform appropriate and effective strat-
egies for HIV vaccine promotion. Descriptive data re-
vealed that nearly 40% were not sure or only somewhat
sure that they would be able to get the HIV vaccine if a
friend/partner was unsupportive. Several previous stud-
ies have indicated that peer support and positive social
norms will be important for facilitating vaccine acceptabil-
ity. Participants in previous studies have reported fear of
negative reactions by family members [7,49] and intimate
partners [7,9,49,56] and concern that others will perceive
their vaccination as an indication of ‘promiscuous’ behavior
[9,52,55]. In the present study, participants who believed
that most people would encourage them to receive an HIV
vaccine and who reported they would be motivated to com-
ply with those recommendations were significantly more
likely to report MVA. Interestingly, additional research in
this sample has indicated that the overwhelming majority
of respondents (94%) would be willing to encourage some-
one to get vaccinated, particularly in circumstances in
Table 4 Bivariate correlates to vaccine acceptability (n = 433)
Characteristic Vaccine acceptability Bivariate
Not very likelya (n = 176) Very likely (n = 257) OR (95% CI) p-value
Demographic
Male 122 (69.3) 117 (45.5) 0.24 (0.12- 0.48) <0.001**
White 163 (92.6) 244 (94.9) 2.16 (0.68 – 6.90) 0.194
Age - mean (SD) 36.3 (9.3) 34.9 (8.1) 0.96 (0.94 – 0.99) 0.018*
Income (n = 432) - mean (SD) $908 (1473) $913 (1125) 1.00 (1.00 - 1.00) 0.629
High school graduate 93 (52.8) 158 (61.5) 1.63 (0.93 – 2.85) 0.088
Uninsured 114 (64.8) 171 (66.5) 1.32 (0.76 – 2.30) 0.331
Married 41 (23.3) 70 (27.2) 1.58 (0.85 – 2.93) 0.144
Behavioral (past 6 months)
Injected drugs 46 (26.1) 100 (38.9) 2.54 (1.41 – 4.58) 0.002**
Injected with unclean needle 9 (5.1) 24 (9.3) 4.53 (1.53 – 13.39) 0.006**
Distributed unclean needleb 5 (2.8) 11 (4.3) 3.23 (0.72 – 14.38) 0.125
Shared injection equipmentc 18 (10.2) 37 (14.4) 2.02 (0.90 – 4.55) 0.090
Had multiple sex partners 35 (19.9) 68 (26.5) 1.53 (0.78 – 2.98) 0.213
Had unprotected sex 120 (68.2) 188 (73.2) 1.49 (0.68 – 2.66) 0.180
Unprotected sex with PWID 24 (13.6) 61 (23.7) 3.33 (1.64 – 6.76) 0.001**
Attitudes about HIV
Severity of HIV 173 (98.3) 254 (98.8) 1.53 (0.13 – 18.25) 0.738
Susceptibility to HIV 23 (13.1) 77 (30.0) 4.63 (2.17 – 9.90) <0.001**
Benefits of HIV vaccine 103 (58.5) 210 (81.7) 5.85 (2.76 – 12.40) <0.001**
Barriers to HIV vaccination 149 (84.7) 195 (75.9) 0.52 (0.26 – 1.03) 0.060
Experiential attitude 127 (72.2) 216 (84.0) 3.14 (1.60 – 6.16) 0.001**
Subjective norms
Descriptive norms 65 (37.1) 130 (50.6) 2.36 (1.34 – 4.18) 0.003**
Injunctive norms 85 (48.6) 166 (64.6) 2.67 (1.47 – 11.13) 0.001**
Agency
Behavioral control 101 (57.4) 175 (68.1) 1.88 (1.05 – 3.34) 0.032*
Self-efficacy 26 (14.8) 57 (22.2) 2.01 (0.98 – 4.13) 0.058
PWID: person who injects drugs; OR: odds ratio; CI: confidence interval; SD: standard deviation.
*p < 0.05; **p < 0.01.
aIncludes responses “very unlikely”, “unlikely”, and “likely”.
bSold, loaned, or gave needle to someone after using it.
cCookers, cottons, and/or rinse water.
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which the partner was perceived to be at risk or pose a risk
for HIV [57]. This finding may serve as preliminary evi-
dence that peer-promotion of HIV vaccination could be a
successful strategy for reaching those most at risk for HIV
in this population. In this context, the lack of a multi-
variate association between descriptive norms and vaccine
acceptability deserves comment. These data suggest that
passive diffusion of vaccine uptake through the social net-
work (i.e. via imitation of others’ behavior) is unlikely, and
underscore the importance of an active approach to peer-
based promotion.
The findings from this study have several theoretical
and methodological implications. This study demonstrates
the importance of assessing both the injunctive and de-
scriptive dimensions of social norms and of coupling mea-
sures of normative beliefs with assessments of individuals'
motivation to comply. Most participants reported that
other people would accept an HIV vaccine, but far fewer
reported that they would be influenced by others' behav-
ior. Although individuals may underestimate their suscep-
tibility to peer influence, data on compliance with norms
may provide preliminary insight into who may be most re-
sponsive to strategies such as social marketing.
The research focused on intent to receive an HIV vac-
cine and, until an HIV vaccine is approved, the corres-
pondence between intentions and actual vaccine uptake
remains unknown. Furthermore, there are limitations of
querying respondents about the specific characteristics of a
hypothetical vaccine; research employing conjoint analysis
[5,6,49,51,58,59] and discrete choice experiments [60] may
yield better insight into relative valuations of various vac-
cine characteristics, project their impact on future accept-
ability, and inform targeted social marketing campaigns.
Though the survey included assessment of several relevant
vaccine-related characteristics (e.g., route of administration,
dosing, vaccine-induced seropositivity) and included an
open-ended item that allowed free-listing of additional bar-
riers to vaccination, the survey did not include direct mea-
sures of two vaccine characteristics determined in previous
research to be important to acceptability: duration of pro-
tection and side effects. Also, while one item measures of
theoretical constructs can be problematic to establishing
psychometric validity and reliability, the use of scales was
not feasible given respondent burden and time constraints
for conducting interviews. Similarly, time constraints lim-
ited our ability to assess psychosocial correlates to vaccine
acceptability by varying levels of vaccine efficacy. The effi-
cacy of future HIV vaccines is currently unknown; however,
it is important to specify an efficacy level in measures of
vaccine acceptability in order to standardize the context of
participants' responses. In the current study, a 90% efficacy
level was chosen as it presented a near ‘best case sce-
nario’ for evaluating acceptability given that the ‘most
realistic scenario’ is difficult to determine at this stage of vac-
cine development and subject to change. Nevertheless, more
research is needed to explore the generalizability of the find-
ings to vaccines of lower efficacy. Similarly, generalization of
findings from this study to other regions of Appalachia
and other rural areas in the US also should be made with
caution, as sociocultural influences across settings are
likely to vary.
Conclusion
In this rural community, despite low perceived vulnerabil-
ity to HIV, most drug users were readily willing to accept
an HIV vaccine. Minimization of out-of-pocket costs will
be essential. Social norms could play a major role in influ-
encing HIV vaccine uptake in this community, and lever-
aged appropriately, could present an effective mechanism
for promoting the vaccine. To plan for effective promotion
and dissemination strategies among populations at high
risk for HIV, continued research is needed to explore in-
fluences on HIV vaccine acceptability among people who
use drugs.
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